- Home
- OSPN vs PRTA Comparison
OSPN vs PRTA Comparison
Compare OSPN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSPN
- PRTA
- Stock Information
- Founded
- OSPN 1991
- PRTA 2012
- Country
- OSPN United States
- PRTA Ireland
- Employees
- OSPN N/A
- PRTA N/A
- Industry
- OSPN EDP Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OSPN Technology
- PRTA Health Care
- Exchange
- OSPN Nasdaq
- PRTA Nasdaq
- Market Cap
- OSPN 702.8M
- PRTA 765.2M
- IPO Year
- OSPN 1998
- PRTA N/A
- Fundamental
- Price
- OSPN $17.18
- PRTA $15.56
- Analyst Decision
- OSPN Strong Buy
- PRTA Buy
- Analyst Count
- OSPN 5
- PRTA 8
- Target Price
- OSPN $16.50
- PRTA $46.00
- AVG Volume (30 Days)
- OSPN 415.1K
- PRTA 336.3K
- Earning Date
- OSPN 02-27-2025
- PRTA 02-20-2025
- Dividend Yield
- OSPN 0.70%
- PRTA N/A
- EPS Growth
- OSPN N/A
- PRTA N/A
- EPS
- OSPN 0.75
- PRTA N/A
- Revenue
- OSPN $244,936,000.00
- PRTA $135,157,000.00
- Revenue This Year
- OSPN $4.28
- PRTA $56.89
- Revenue Next Year
- OSPN $3.43
- PRTA N/A
- P/E Ratio
- OSPN $23.05
- PRTA N/A
- Revenue Growth
- OSPN 7.05
- PRTA 47.92
- 52 Week Low
- OSPN $9.22
- PRTA $11.70
- 52 Week High
- OSPN $20.36
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- OSPN 34.19
- PRTA 59.65
- Support Level
- OSPN $19.32
- PRTA $13.69
- Resistance Level
- OSPN $20.36
- PRTA $15.09
- Average True Range (ATR)
- OSPN 0.82
- PRTA 0.91
- MACD
- OSPN -0.23
- PRTA 0.13
- Stochastic Oscillator
- OSPN 6.33
- PRTA 68.56
About OSPN OneSpan Inc.
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).